Kathy Vernovsky

TL;DR: Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.

TL;DR: A highly sensitive multiplexed clinical assay that performs very well with nucleic acid derived from formalin fixation and paraffin embedding tissue, and tests for 120 previously described mutations in 13 cancer genes, establishes a platform for real‐time targeted genotyping that can be widely adopted.

TL;DR: The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs.

TL;DR: The results suggest that ancillary NGS testing offers advantages over FISH, although studies with larger cohorts are needed to verify these findings.